玻璃体腔内注射康柏西普治疗非缺血型RVO的短期疗效观察
|
摘要
目的探究玻璃体腔内注射康柏西普治疗非缺血型视网膜静脉堵塞(RVO)的短期临床疗效。方法回顾性分析2015年3月—2017年3月42例于我院就诊并确诊为非缺血型RVO患者的临床资料,全部患者采用玻璃体腔内注射康柏西普眼用注射液0.05 ml治疗。比较患者治疗前后的最佳矫正视力(BCVA)和黄斑中心视网膜厚度(CMT),并观察治疗后患者不良反应及并发症发生情况。结果 42例患者42眼中,有13眼行1次注射,有19眼行2次注射,有10眼行3次注射。治疗前,患者最小视力分辨率的对数值(log VA)为(0.61±0.15),首次注射后1个月的log VA为(0.39±0.10),与注射前比较,log VA差异有统计学意义(t=7.909,P=0.000),第一次注射后1个月、2个月及6个月的log VA比较差异有统计学意义(F=15.349,P=0.000),且两两比较,差异有统计学意义(P<0.05)。治疗前,患者初始CMT为(538.46±114.76)μm,首次注射后1周的CMT为(284.76±65.26)μm,与注射前比较,CMT差异有统计学意义(t=12.454,P=0.000),第一次注射后,随访6个月,仅有4例(9.52%)出现一次性眼压过高,未见其他不良反应或并发症。结论采用玻璃体腔内注射康柏西普治疗非缺血型RVO短期疗效明确,能明显提高患者视力,降低患者CMT,且安全性高。
Objective To explore the short-term clinical efficacy of intravitreal injection of Conbercept in the treatment of non-ischemic RVO.Methods The clinical data of forty-two patients diagnosed as non-ischemic RVO in Suzhou Science & Technology Town Hospital Affiliated to Nanjing Medical University from March 2015 to March 2017 were retrospectively analyzed.All patients were treated with intravitreal injection of 0.05 ml Conbercept ophthalmic injection.The best corrected visual acuity(BCVA) and central macular thickness(CMT) were compared among patients before and after treatment,and the occurrence of adverse reactions and complications were observed after treatment.Results Among 42 eyes of 42 patients,13 eyes were given 1 injection,and 19 eyes were given 2 injections and 10 eyes for 3 injections.Before treatment,the logarithm of minimum visual acuity(log VA) was(0.61±0.15),and the log VA at 1 month after first injection was(0.39±0.10).Compared with before injection,the difference in log VA was statistically significant(t=7.909,P=0.000),and there were statistically significant differences in log VA at 1 month,2 months and 6 months after first injection(F=15.349,P=0.000),and there were statistically significant differences in the comparison between any two(P<0.05).Before treatment,the initial CMT was(538.46±114.76) μm,and the CMT at 1 week after first injection was(284.76±65.26) μm.Compared with before injection,the difference in CMT was statistically significant(t=12.454,P=0.000).After first injection,6-month follow-up was performed on patients,and there was only 4 cases(9.52%) with one-time high intraocular pressure,and there were no other adverse reactions or complications.Conclusion Intravitreal injection of Conbercept has definite short-term efficacy on non-ischemic RVO,and it can significantly improve the visual acuity and decrease the CMT,and it has high safety.
Objective To explore the short-term clinical efficacy of intravitreal injection of Conbercept in the treatment of non-ischemic RVO.Methods The clinical data of forty-two patients diagnosed as non-ischemic RVO in Suzhou Science & Technology Town Hospital Affiliated to Nanjing Medical University from March 2015 to March 2017 were retrospectively analyzed.All patients were treated with intravitreal injection of 0.05 ml Conbercept ophthalmic injection.The best corrected visual acuity(BCVA) and central macular thickness(CMT) were compared among patients before and after treatment,and the occurrence of adverse reactions and complications were observed after treatment.Results Among 42 eyes of 42 patients,13 eyes were given 1 injection,and 19 eyes were given 2 injections and 10 eyes for 3 injections.Before treatment,the logarithm of minimum visual acuity(log VA) was(0.61±0.15),and the log VA at 1 month after first injection was(0.39±0.10).Compared with before injection,the difference in log VA was statistically significant(t=7.909,P=0.000),and there were statistically significant differences in log VA at 1 month,2 months and 6 months after first injection(F=15.349,P=0.000),and there were statistically significant differences in the comparison between any two(P<0.05).Before treatment,the initial CMT was(538.46±114.76) μm,and the CMT at 1 week after first injection was(284.76±65.26) μm.Compared with before injection,the difference in CMT was statistically significant(t=12.454,P=0.000).After first injection,6-month follow-up was performed on patients,and there was only 4 cases(9.52%) with one-time high intraocular pressure,and there were no other adverse reactions or complications.Conclusion Intravitreal injection of Conbercept has definite short-term efficacy on non-ischemic RVO,and it can significantly improve the visual acuity and decrease the CMT,and it has high safety.
引文
[1] 刘卫.视网膜静脉阻塞继发黄斑水肿的治疗进展[J].中国眼耳鼻喉科杂志,2015,31(4):785-788
[2] 陆秉文,吴星伟.苦碟子注射液治疗非缺血型视网膜静脉阻塞临床研究[J].中国中医眼科杂志,2013,23(3):179-182
[3] 胥静,吴烈.视网膜静脉阻塞黄斑水肿的发病机制及治疗进展[J].现代中医临床,2018,25(2):50-54
[4] 章桂芳,黄永健.苦碟子注射液对非缺血型视网膜静脉阻塞的临床疗效及对血液流变学的影响[J].中国临床药理学杂志,2011,27(8):580-583
[5] 张伟,毕大光,谷树严.视网膜静脉阻塞激光光凝的时机选择[J].国际眼科杂志,2014,14(8):1403-1406
[6] 王彬,贾淑琴,霍建新.视网膜静脉阻塞的诊断与治疗研究进展[J].国际眼科杂志,2014,14(7):1227-1230
[7] 邢凯,亢泽峰.玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J].山东大学耳鼻喉眼学报,2016,30(1):80-82
[8] 高健,赵冰莹,许亚静,等.康柏西普治疗视网膜静脉阻塞继发黄斑水肿的回顾性观察分析[J].临床眼科杂志,2017,25(6):494-497
[9] 陈甲兴,唐宁.视网膜静脉阻塞相关因素的临床观察[J].国际眼科杂志,2014,14(2):354-357
[10] 童念庭,张珍珍,宫媛媛,等.地奥司明治疗非缺血型RVO的疗效观察[J].国际眼科杂志,2013,13(3):580-582
[11] Jing Feng,Tong Zhao,Yan Zhang,et al.Differences in Aqueous Concentrations of Cytokines in Macular Edema Secondary to Branch and Central Retinal Vein Occlusion[J].Plos One,2013,8(7):68149
[12] Tsagkataki M,Papathomas T,Lythgoe D,et al.Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion[J].Seminars in Ophthalmology,2015,30(5-6):1-8
[13] Pielen A,Mirshahi A,Feltgen N,et al.Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES):six‐month results of a prospective randomized clinical trial[J].Acta Ophthalmologica,2015,93(1):29-37
[14] 毛剑波,褚梦琪,陈亦棋,等.玻璃体腔注射康柏西普治疗视网膜静脉阻塞黄斑水肿短期疗效观察[J].中华眼底病杂志,2016,32(4):372-376
[2] 陆秉文,吴星伟.苦碟子注射液治疗非缺血型视网膜静脉阻塞临床研究[J].中国中医眼科杂志,2013,23(3):179-182
[3] 胥静,吴烈.视网膜静脉阻塞黄斑水肿的发病机制及治疗进展[J].现代中医临床,2018,25(2):50-54
[4] 章桂芳,黄永健.苦碟子注射液对非缺血型视网膜静脉阻塞的临床疗效及对血液流变学的影响[J].中国临床药理学杂志,2011,27(8):580-583
[5] 张伟,毕大光,谷树严.视网膜静脉阻塞激光光凝的时机选择[J].国际眼科杂志,2014,14(8):1403-1406
[6] 王彬,贾淑琴,霍建新.视网膜静脉阻塞的诊断与治疗研究进展[J].国际眼科杂志,2014,14(7):1227-1230
[7] 邢凯,亢泽峰.玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J].山东大学耳鼻喉眼学报,2016,30(1):80-82
[8] 高健,赵冰莹,许亚静,等.康柏西普治疗视网膜静脉阻塞继发黄斑水肿的回顾性观察分析[J].临床眼科杂志,2017,25(6):494-497
[9] 陈甲兴,唐宁.视网膜静脉阻塞相关因素的临床观察[J].国际眼科杂志,2014,14(2):354-357
[10] 童念庭,张珍珍,宫媛媛,等.地奥司明治疗非缺血型RVO的疗效观察[J].国际眼科杂志,2013,13(3):580-582
[11] Jing Feng,Tong Zhao,Yan Zhang,et al.Differences in Aqueous Concentrations of Cytokines in Macular Edema Secondary to Branch and Central Retinal Vein Occlusion[J].Plos One,2013,8(7):68149
[12] Tsagkataki M,Papathomas T,Lythgoe D,et al.Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion[J].Seminars in Ophthalmology,2015,30(5-6):1-8
[13] Pielen A,Mirshahi A,Feltgen N,et al.Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES):six‐month results of a prospective randomized clinical trial[J].Acta Ophthalmologica,2015,93(1):29-37
[14] 毛剑波,褚梦琪,陈亦棋,等.玻璃体腔注射康柏西普治疗视网膜静脉阻塞黄斑水肿短期疗效观察[J].中华眼底病杂志,2016,32(4):372-376